Tenderwize
Zurück zur Suche

Open house Risperidone rebate agreements

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 05, 2027 · 220 days left·Open·Supplies·Framework
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Risperidon in der Darreichungsform Pulver und Lösungsmittel zur Herstellung einer Injektionslösung, ATC N05AX08

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

20 / 100

Risikofaktoren

No estimated value is provided. It is unclear what the potential volume or revenue from this agreement may be.

For paper submissions, two original copies must be sent by post; electronic submissions require a qualified electronic...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply of the pharmaceutical product Risperidone in the form of powder and solvent for injection solution (ATC N05AX08)
  • Conclusion of a non-exclusive rebate agreement with AOK Bayern
Vollständige Zusammenfassung anzeigen

This is an open-house model (not a standard procurement) by AOK Bayern for non-exclusive rebate agreements on Risperidone (powder and solvent for injection solution, ATC N05AX08). Any interested pharmaceutical company that meets the eligibility criteria can join. The agreement runs from 1 June 2025 to 31 May 2027. There is no competitive selection; contracts are concluded with all qualified suppliers. No estimated contract value is provided.

Risiken

No estimated value is provided. It is unclear what the potential volume or revenue from this agreement may be.

For paper submissions, two original copies must be sent by post; electronic submissions require a qualified electronic...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible to participate.

Administrative

  • Submission of a signed self-declaration of reliability.
  • Submission of the signed contract and annex (list of medicines subject to the agreement).

Anforderungen können unvollständig sein.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open house Risperidone rebate agreements

Non-exclusive rebate agreement for Risperidone in the form of powder and solvent for injection solution. All interested pharmaceutical companies that meet the eligibility criteria can participate.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Frist

Deadline Apr 05, 2027

Vergabedetails

Veröffentlichungsdatum
15 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
249452-2025

Dokumente (2)

Ähnliche Ausschreibungen